Guidelines
The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.
The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.
They are published in association with the British Society for Haematology (BSH) and published in the British Journal of Haematology. The Chair of the UKMS Guidelines Group is a co-opted member of the BSH Haemato-oncology Task Force, which oversees the production of all BSH guidelines relating to the haematological malignancies. The writing groups of our guidelines contain members of the UKMS Executive Committee and other experts in the disease.
In a rapidly moving field such as the management of multiple myeloma, it is a challenge to ensure that our guidelines are up to date. They are consequently reviewed at regular intervals, and archived when they are felt to be obsolete. The UKMS Executive feels strongly that our treatment-related guidelines should recommend the best available licensed therapies, and not be affected by what treatments are funded by the NHS at the time the guidelines are written.
We believe that the UKMS/BSH myeloma guidelines are improved as a result of the close collaboration of the group with Myeloma UK to ensure that they are ‘patient-focussed.
Chair. Dr Tracey Chan
Consultant Haematologist
Chair. Dr Tracey Chan
Consultant Haematologist
Dr Chan graduated from The University of Birmingham (UoB) Medical School and completed her PhD and haematology training in the West Midlands. She has been a consultant haematologist since 2020, initially at Worcester Acute Hospitals NHS Trust and, since 2023 at University Hospitals Birmingham NHS Trust.
Her clinical interests are myeloma and plasma cell disorders with particular interest in improving diagnostics in blood cancer. In addition to her clinical role, she reports flow cytometry at the UoB Clinical Immunology Service to diagnose haematological malignancies for the Midlands Integrated Regional Haemato-Oncology Service and leads research to develop new tests for patients with plasma cell disorders.
She is a member of the British Society of Haematology Haemato-Oncology Guidelines Task Force.